<i>SIGLEC1</i> as a novel prognostic factor is regulated by Yiqi Huayu Jiedu Decoction in colorectal cancer

We studied the prognostic value of <i>SIGLEC1</i> in colorectal cancer (CRC) using bioinformatics. <i>SIGLEC1</i> exhibited differential expression between the tumor and control samples, and improved survival was observed in patients with increased <i>SIGLEC1</i> expression. The univariate and multivariate analyses confirmed <i>SIGLEC1</i> as an independent prognostic factor for CRC, based on which a nomogram was constructed for predicting survival in patients with CRC. Additionally, higher <i>SIGLEC1</i> expression was correlated with increased immunological/stromal/ESTIMATE scores as well as immune cell infiltration and was strongly and positively associated with T helper cells and macrophages. Furthermore, significant positive correlations were observed between SIGLEC1 expression and inhibitory/coinhibitory immunological genes. Additionally, the TIDE results of patients with CRC showed that increased <i>SIGLEC1</i> expression was related to poorer immunotherapeutic responses. In clinical samples from patients with CRC, a decrease in <i>SIGLEC1</i> expression was noted compared to para-cancerous tissues and samples from patients who received Yiqi Huayu Jiedu Decoction (YHJD) treatment. The <i>in vivo</i> results indicated the superior efficacy of YHJD against CRC in inhibiting tumor metastasis. Our study demonstrates that SIGLEC1 serves as a prognostic factor for CRC, strongly linked to immune response, and can be modulated by YHJD, suggesting novel avenues for CRC treatment.